article thumbnail

CAR-T therapy could “alter the treatment paradigm” of multiple sclerosis

Drug Discovery World

. “This approval is a critically necessary step that paves the way to enrol patients with treatment-refractory progressive MS for whom there are no currently available treatment options in the KYSA-7 trial.

Therapies 312
article thumbnail

Amgen reports positive results for treatment of IgG4-RD

Drug Discovery World

Amgen has reported positive topline results from its randomised, double-blind, multicentre, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its treatment for Immunoglobulin G4-related disease (IgG4-RD). ” Amgen is now planning to file for approval in the US following results on the MITIGATE study. .”

Treatment 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK researchers discover new treatment target for atheroschlerosis

Drug Discovery World

Together with beLAB1407, we aim to develop a new treatment regime that could play a significant role in reducing one of the key factors in cardiovascular diseases.” The new treatment is anticipated to be able to help patients who are present at the hospital having survived a heart attack or stroke.

Treatment 147
article thumbnail

FDA grants Fast Track designation to prostate cancer treatment

Drug Discovery World

Biopharmaceutical company Syncromune has had its lead-candidate for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) granted Fast Track designation by the FDA. Reece Armstrong, Editor, DDW The post FDA grants Fast Track designation to prostate cancer treatment appeared first on Drug Discovery World (DDW).

FDA 147
article thumbnail

New study uses genetics to identify best sepsis treatment

Drug Discovery World

Having a more detailed understanding of sepsis at a molecular level could identify those who would benefit from different therapies, helping to design rapid tests, organise clinical trials, and develop targeted treatments based on the individual immune response.

article thumbnail

“Highly encouraging” results for treatment-resistant schizophrenia drug

Drug Discovery World

Milan-based Newron Pharmaceuticals has reported “exceptional” one-year results from study 014/15 into evenamide as an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS). The post “Highly encouraging” results for treatment-resistant schizophrenia drug appeared first on Drug Discovery World (DDW).

Treatment 147
article thumbnail

Treatment potential for immunotherapy-induced cytokine release syndrome  

Drug Discovery World

Cancer immunotherapies, such as bispecific antibodies and CAR-T cell therapy, are rapidly moving into earlier lines of treatment in many tumour types, with these markets anticipated to grow to US$100bn+ (~35% CAGR) by 2030 3. In the US, the American Cancer Society estimates that there will be 24.6 million cases of cancer by 2030 1,2.

Treatment 162